Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
This $3 Biotech Could Be Worth $11.45, Analyst Says
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP